Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis.
Identifieur interne : 000125 ( Main/Corpus ); précédent : 000124; suivant : 000126Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis.
Auteurs : Awadhesh K. Singh ; Clare L. Gillies ; Ritu Singh ; Akriti Singh ; Yogini Chudasama ; Briana Coles ; Sam Seidu ; Francesco Zaccardi ; Melanie J. Davies ; Kamlesh KhuntiSource :
- Diabetes, obesity & metabolism [ 1463-1326 ] ; 2020.
Abstract
AIM
To estimate the prevalence of both cardiometabolic and other co-morbidities in patients with COVID-19, and to estimate the increased risk of severity of disease and mortality in people with co-morbidities.
MATERIALS AND METHODS
Medline, Scopus and the World Health Organization website were searched for global research on COVID-19 conducted from January 2019 up to 23 April 2020. Study inclusion was restricted to English language publications, original articles that reported the prevalence of co-morbidities in individuals with COVID-19, and case series including more than 10 patients. Eighteen studies were selected for inclusion. Data were analysed using random effects meta-analysis models.
RESULTS
Eighteen studies with a total of 14 558 individuals were identified. The pooled prevalence for co-morbidities in patients with COVID-19 disease was 22.9% (95% CI: 15.8 to 29.9) for hypertension, 11.5% (9.7 to 13.4) for diabetes, and 9.7% (6.8 to 12.6) for cardiovascular disease (CVD). For chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), cerebrovascular disease and cancer, the pooled prevalences were all less than 4%. With the exception of cerebrovascular disease, all the other co-morbidities presented a significantly increased risk for having severe COVID-19. In addition, the risk of mortality was significantly increased in individuals with CVD, COPD, CKD, cerebrovascular disease and cancer.
CONCLUSIONS
In individuals with COVID-19, the presence of co-morbidities (both cardiometabolic and other) is associated with a higher risk of severe COVID-19 and mortality. These findings have important implications for public health with regard to risk stratification and future planning.
DOI: 10.1111/dom.14124
PubMed: 32573903
PubMed Central: PMC7361304
Links to Exploration step
pubmed:32573903Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis.</title><author><name sortKey="Singh, Awadhesh K" sort="Singh, Awadhesh K" uniqKey="Singh A" first="Awadhesh K" last="Singh">Awadhesh K. Singh</name><affiliation><nlm:affiliation>GD Hospital & Diabetes Institute, Kolkata, India.</nlm:affiliation></affiliation></author><author><name sortKey="Gillies, Clare L" sort="Gillies, Clare L" uniqKey="Gillies C" first="Clare L" last="Gillies">Clare L. Gillies</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Ritu" sort="Singh, Ritu" uniqKey="Singh R" first="Ritu" last="Singh">Ritu Singh</name><affiliation><nlm:affiliation>GD Hospital & Diabetes Institute, Kolkata, India.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Akriti" sort="Singh, Akriti" uniqKey="Singh A" first="Akriti" last="Singh">Akriti Singh</name><affiliation><nlm:affiliation>College of Medicine and JNM Hospital, Kalyani, Nadia, West Bengal, India.</nlm:affiliation></affiliation></author><author><name sortKey="Chudasama, Yogini" sort="Chudasama, Yogini" uniqKey="Chudasama Y" first="Yogini" last="Chudasama">Yogini Chudasama</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Coles, Briana" sort="Coles, Briana" uniqKey="Coles B" first="Briana" last="Coles">Briana Coles</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Seidu, Sam" sort="Seidu, Sam" uniqKey="Seidu S" first="Sam" last="Seidu">Sam Seidu</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Zaccardi, Francesco" sort="Zaccardi, Francesco" uniqKey="Zaccardi F" first="Francesco" last="Zaccardi">Francesco Zaccardi</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Davies, Melanie J" sort="Davies, Melanie J" uniqKey="Davies M" first="Melanie J" last="Davies">Melanie J. Davies</name><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Khunti, Kamlesh" sort="Khunti, Kamlesh" uniqKey="Khunti K" first="Kamlesh" last="Khunti">Kamlesh Khunti</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32573903</idno><idno type="pmid">32573903</idno><idno type="doi">10.1111/dom.14124</idno><idno type="pmc">PMC7361304</idno><idno type="wicri:Area/Main/Corpus">000125</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000125</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis.</title><author><name sortKey="Singh, Awadhesh K" sort="Singh, Awadhesh K" uniqKey="Singh A" first="Awadhesh K" last="Singh">Awadhesh K. Singh</name><affiliation><nlm:affiliation>GD Hospital & Diabetes Institute, Kolkata, India.</nlm:affiliation></affiliation></author><author><name sortKey="Gillies, Clare L" sort="Gillies, Clare L" uniqKey="Gillies C" first="Clare L" last="Gillies">Clare L. Gillies</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Ritu" sort="Singh, Ritu" uniqKey="Singh R" first="Ritu" last="Singh">Ritu Singh</name><affiliation><nlm:affiliation>GD Hospital & Diabetes Institute, Kolkata, India.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Akriti" sort="Singh, Akriti" uniqKey="Singh A" first="Akriti" last="Singh">Akriti Singh</name><affiliation><nlm:affiliation>College of Medicine and JNM Hospital, Kalyani, Nadia, West Bengal, India.</nlm:affiliation></affiliation></author><author><name sortKey="Chudasama, Yogini" sort="Chudasama, Yogini" uniqKey="Chudasama Y" first="Yogini" last="Chudasama">Yogini Chudasama</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Coles, Briana" sort="Coles, Briana" uniqKey="Coles B" first="Briana" last="Coles">Briana Coles</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Seidu, Sam" sort="Seidu, Sam" uniqKey="Seidu S" first="Sam" last="Seidu">Sam Seidu</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Zaccardi, Francesco" sort="Zaccardi, Francesco" uniqKey="Zaccardi F" first="Francesco" last="Zaccardi">Francesco Zaccardi</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Davies, Melanie J" sort="Davies, Melanie J" uniqKey="Davies M" first="Melanie J" last="Davies">Melanie J. Davies</name><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Khunti, Kamlesh" sort="Khunti, Kamlesh" uniqKey="Khunti K" first="Kamlesh" last="Khunti">Kamlesh Khunti</name><affiliation><nlm:affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Diabetes, obesity & metabolism</title><idno type="eISSN">1463-1326</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>AIM</b></p><p>To estimate the prevalence of both cardiometabolic and other co-morbidities in patients with COVID-19, and to estimate the increased risk of severity of disease and mortality in people with co-morbidities.</p></div><div type="abstract" xml:lang="en"><p><b>MATERIALS AND METHODS</b></p><p>Medline, Scopus and the World Health Organization website were searched for global research on COVID-19 conducted from January 2019 up to 23 April 2020. Study inclusion was restricted to English language publications, original articles that reported the prevalence of co-morbidities in individuals with COVID-19, and case series including more than 10 patients. Eighteen studies were selected for inclusion. Data were analysed using random effects meta-analysis models.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Eighteen studies with a total of 14 558 individuals were identified. The pooled prevalence for co-morbidities in patients with COVID-19 disease was 22.9% (95% CI: 15.8 to 29.9) for hypertension, 11.5% (9.7 to 13.4) for diabetes, and 9.7% (6.8 to 12.6) for cardiovascular disease (CVD). For chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), cerebrovascular disease and cancer, the pooled prevalences were all less than 4%. With the exception of cerebrovascular disease, all the other co-morbidities presented a significantly increased risk for having severe COVID-19. In addition, the risk of mortality was significantly increased in individuals with CVD, COPD, CKD, cerebrovascular disease and cancer.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>In individuals with COVID-19, the presence of co-morbidities (both cardiometabolic and other) is associated with a higher risk of severe COVID-19 and mortality. These findings have important implications for public health with regard to risk stratification and future planning.</p></div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32573903</PMID><DateRevised><Year>2020</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1463-1326</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Jun</Month><Day>23</Day></PubDate></JournalIssue><Title>Diabetes, obesity & metabolism</Title><ISOAbbreviation>Diabetes Obes Metab</ISOAbbreviation></Journal><ArticleTitle>Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/dom.14124</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To estimate the prevalence of both cardiometabolic and other co-morbidities in patients with COVID-19, and to estimate the increased risk of severity of disease and mortality in people with co-morbidities.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Medline, Scopus and the World Health Organization website were searched for global research on COVID-19 conducted from January 2019 up to 23 April 2020. Study inclusion was restricted to English language publications, original articles that reported the prevalence of co-morbidities in individuals with COVID-19, and case series including more than 10 patients. Eighteen studies were selected for inclusion. Data were analysed using random effects meta-analysis models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighteen studies with a total of 14 558 individuals were identified. The pooled prevalence for co-morbidities in patients with COVID-19 disease was 22.9% (95% CI: 15.8 to 29.9) for hypertension, 11.5% (9.7 to 13.4) for diabetes, and 9.7% (6.8 to 12.6) for cardiovascular disease (CVD). For chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), cerebrovascular disease and cancer, the pooled prevalences were all less than 4%. With the exception of cerebrovascular disease, all the other co-morbidities presented a significantly increased risk for having severe COVID-19. In addition, the risk of mortality was significantly increased in individuals with CVD, COPD, CKD, cerebrovascular disease and cancer.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In individuals with COVID-19, the presence of co-morbidities (both cardiometabolic and other) is associated with a higher risk of severe COVID-19 and mortality. These findings have important implications for public health with regard to risk stratification and future planning.</AbstractText><CopyrightInformation>© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Awadhesh K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8374-4536</Identifier><AffiliationInfo><Affiliation>GD Hospital & Diabetes Institute, Kolkata, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillies</LastName><ForeName>Clare L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8417-9700</Identifier><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Ritu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>GD Hospital & Diabetes Institute, Kolkata, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Akriti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Medicine and JNM Hospital, Kalyani, Nadia, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chudasama</LastName><ForeName>Yogini</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coles</LastName><ForeName>Briana</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seidu</LastName><ForeName>Sam</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8335-7018</Identifier><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaccardi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Melanie J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9987-9371</Identifier><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khunti</LastName><ForeName>Kamlesh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>National Institute for Health Research</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diabetes Obes Metab</MedlineTA><NlmUniqueID>100883645</NlmUniqueID><ISSNLinking>1462-8902</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">co-morbidities</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32573903</ArticleId><ArticleId IdType="doi">10.1111/dom.14124</ArticleId><ArticleId IdType="pmc">PMC7361304</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-269.</Citation></Reference><Reference><Citation>Worldometers. Coronavirus Update (Live). 2020. https://www.worldometers.info/coronavirus/. Accessed 4th May 2020.</Citation></Reference><Reference><Citation>The National Health Commission of China. New coronavirus pneumonia prevention and control program, 6th ed. (in Chinese). 2020. http://en.nhc.gov.cn/2020-03/29/c_78468.htm. Accessed May 1, 2020.</Citation></Reference><Reference><Citation>BBC News. ‘Window of Opportunity’ to Stop Coronavirus: @BBCNews. 2020. https://www.bbc.com/news/world-asia-china-51368873. Accessed 4th May 2020.</Citation></Reference><Reference><Citation>Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. Lancet. 2020;2(4):PE201-PE208.</Citation></Reference><Reference><Citation>Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a Nationwide analysis. Eur Respir J. 2020;55:2000547.</Citation></Reference><Reference><Citation>Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.</Citation></Reference><Reference><Citation>Adams JG, Walls RM. Supporting the health care workforce during the COVID-19 global epidemic. JAMA. 2020;323:1439.</Citation></Reference><Reference><Citation>Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):e35.</Citation></Reference><Reference><Citation>Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95.</Citation></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.</Citation></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.</Citation></Reference><Reference><Citation>The World Health Organisation. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov. Accessed April 23, 2020.</Citation></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605.</Citation></Reference><Reference><Citation>Higgins JP, Thomas J, Chandler J. Cochrane Handbook for Systematic Reviews of Interventions. London, England: Wiley; 2011.</Citation></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.</Citation></Reference><Reference><Citation>Carpenter CJ. A trim and fill examination of the extent of publication bias in communication research. Commun Methods Meas. 2012;6(1):41-55.</Citation></Reference><Reference><Citation>Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region - case series. N Engl J Med. 2020;382:2012-2022.</Citation></Reference><Reference><Citation>Cao J, Tu WJ, Cheng W, et al. Clinical features and short-term outcomes of 102 patients with Corona virus disease 2019 in Wuhan, China. Clin Infect Dis. 2020;2:2.</Citation></Reference><Reference><Citation>Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.</Citation></Reference><Reference><Citation>Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J. 2020;20:20.</Citation></Reference><Reference><Citation>Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;12:12.</Citation></Reference><Reference><Citation>McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a long-term Care Facility in King County, Washington. N Engl J Med. 2020;382:2005-2011.</Citation></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052.</Citation></Reference><Reference><Citation>Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475-481.</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.</Citation></Reference><Reference><Citation>Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458-464.</Citation></Reference><Reference><Citation>Chen T, Dai Z, Mo P, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. J Gerontol Ser A. 2020;11:11.</Citation></Reference><Reference><Citation>Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;20:20.</Citation></Reference><Reference><Citation>CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;3(13):382-386.</Citation></Reference><Reference><Citation>Feng Y, Ling Y, Bai T, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med. 2020;10:10.</Citation></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;6:6.</Citation></Reference><Reference><Citation>Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. http://doi:10.1001/jamacardio.2020.1017.</Citation></Reference><Reference><Citation>Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/Metabol Res Rev. 2020;e3319. https://doi.org/10.1002/dmrr.3319.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.</Citation></Reference><Reference><Citation>Lian J, Jin X, Hao S, et al. Analysis of epidemiological and clinical features in older patients with Corona virus disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis. 2020;25:25.</Citation></Reference><Reference><Citation>Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): a Nationwide analysis of China. Eur Respir J. 2020;8:8.</Citation></Reference><Reference><Citation>Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133(9):1025-1031.</Citation></Reference><Reference><Citation>Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol. 2020;21:21.</Citation></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061.</Citation></Reference><Reference><Citation>Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020;16:16.</Citation></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.</Citation></Reference><Reference><Citation>Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020. https://doi:10.1001/jamainternmed.2020.0994.</Citation></Reference><Reference><Citation>Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. https://doi.org/10.1111/all.14238.</Citation></Reference><Reference><Citation>ICNARC. https://www.icnarc.org/About/Latest-News/2020/04/04/Report-On-2249-Patients-Critically-Ill-With-Covid-19. Accessed April 9, 2020.</Citation></Reference><Reference><Citation>Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020.28(7):1195-1199.</Citation></Reference><Reference><Citation>Chen YM, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.03.25.20043133v1.</Citation></Reference><Reference><Citation>Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health 2020.1-14.</Citation></Reference><Reference><Citation>Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531-538.</Citation></Reference><Reference><Citation>Wells, G. A, Shea, B., O'Connel, D. et al. The Newcastle-Ottawa scale (NOS) for assessing the quailty of nonrandomised studies in meta-analyses. http://www.ohrica/programs/clinical_epidemiology/oxford htm 2009 Feb 1</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000125 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000125 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32573903
|texte= Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32573903" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |